Core Viewpoint - The stock of Jiangsu Hengrui Medicine Co., Ltd. (02617) surged nearly 14%, reaching HKD 166.1 with a trading volume of HKD 112 million, following the announcement of positive exploratory Phase II clinical trial results for its core product, Tiengogatin, in treating cholangiocarcinoma published in a high-impact journal [1] Group 1: Clinical Trial Results - Tiengogatin, a next-generation FGFR2 inhibitor, demonstrated durable responses and prolonged survival in cholangiocarcinoma patients during the Phase II study, prompting researchers to support the initiation of a Phase III registration trial [1] - The study was commented on by researchers from the MD Anderson Cancer Center, highlighting the search for next-generation FGFR2 inhibitors [1] Group 2: Product Development and Regulatory Status - Tiengogatin is an innovative multi-target small molecule kinase inhibitor developed in-house, targeting tumor cells and improving the tumor microenvironment for anti-tumor effects [1] - The product has received orphan drug designation (ODD) and fast track designation from the FDA for cholangiocarcinoma, and has been included in the breakthrough therapy and priority review lists by China's NMPA, as well as receiving ODD from the European EMA for cholangiocarcinoma treatment [1]
药捷安康-B拉升近14% 近日宣布在《柳叶刀》子刊发表替恩戈替尼积极临床结果